Análisis molecular del cáncer de colon esporádico

• Claudia Hurtado ^[1] ; Ana María Wielandt ^[1] ; Alejandro J Zárate ^[1] ; Udo Kronberg ^[1] ; Magdalena Castro ^[1] ; Ken Yamagiwa ^[2] ; Takashi Ito ^[2] ; Yoshinobu Eishi ^[2] ; Luis Contreras ^[2] ; Francisco López-Köstner ^[1]
  1. [1] Clínica Las Condes

     Clínica Las Condes

     Santiago, Chile

     
  2. [2] Tokyo Medical and Dental University

     Tokyo Medical and Dental University

     Japón

     
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 143, Nº. 3, 2015, págs. 310-319
• Idioma: español
• Títulos paralelos:
  • Molecular analysis of sporadic colon cancer
• Enlaces
  • Texto completo
• Resumen

  • Background: In Chile, colorectal cancer (CRC) is often diagnosed in late stages. Thus, surgical treatment must be complemented with chemotherapy. KRAS mutations and microsatellite instability have been detected in these tumors. However, the response to treatment in patients without KRAS mutations varies and requires a better understanding. Aim: To determine the frequency and distribution of somatic point mutations in KRAS, BRAF and PIK3CA genes and microsatellite instability status (MSI) in patients with colon cancer (CC). Material and Methods: A prospective observational study of patients undergoing surgery for colon cancer. Tumor-derived DNA was analyzed by polymerase chain reaction (PCR) for the most frequent mutations of KRAS, BRAF and PIK3CA. PCR was also used to analyze MSI. Results: Fifty-eight patients with sporadic CC were analyzed, 16 showed KRAS mutations (G12R, G12D, G12V, G13D) and out of the 42 patients that did not show any mutation, 10 had mutations in BRAF (V600E) and PIK3CA (E542K, E545D, E545K, Q546E, H1047R). BRAF mutations alone or in combination with PIK3CA mutations were observed in 27% of high MSI tumors and in 2% of tumors without instability (p < 0.049). A higher percentage of high MSI tumors were located in the right colon (p < 0.001), and showed BRAF mutation (p < 0.020). Conclusions: The highest percentage of high MSI and BRAF mutations was observed in the right colon. Therefore, this study suggests the presence of different molecular features between right and left colon tumors that should be considered when defining the therapeutic management.